ELTX vs. CRVS, TNGX, AVIR, LFCR, ATXS, RZLT, AQST, FHTX, ALMS, and ANNX
Should you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Corvus Pharmaceuticals (CRVS), Tango Therapeutics (TNGX), Atea Pharmaceuticals (AVIR), Lifecore Biomedical (LFCR), Astria Therapeutics (ATXS), Rezolute (RZLT), Aquestive Therapeutics (AQST), Foghorn Therapeutics (FHTX), Alumis (ALMS), and Annexon (ANNX). These companies are all part of the "pharmaceutical preparations" industry.
Elicio Therapeutics vs.
Elicio Therapeutics (NASDAQ:ELTX) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, community ranking, analyst recommendations, risk and institutional ownership.
35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 28.7% of Elicio Therapeutics shares are held by company insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Corvus Pharmaceuticals' return on equity of -70.71% beat Elicio Therapeutics' return on equity.
Corvus Pharmaceuticals has lower revenue, but higher earnings than Elicio Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.
Elicio Therapeutics has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.
Elicio Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 33.33%. Corvus Pharmaceuticals has a consensus target price of $15.00, indicating a potential upside of 296.83%. Given Corvus Pharmaceuticals' higher probable upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Elicio Therapeutics.
In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Elicio Therapeutics. MarketBeat recorded 3 mentions for Corvus Pharmaceuticals and 2 mentions for Elicio Therapeutics. Corvus Pharmaceuticals' average media sentiment score of 0.24 beat Elicio Therapeutics' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.
Corvus Pharmaceuticals received 288 more outperform votes than Elicio Therapeutics when rated by MarketBeat users. However, 87.50% of users gave Elicio Therapeutics an outperform vote while only 61.97% of users gave Corvus Pharmaceuticals an outperform vote.
Summary
Corvus Pharmaceuticals beats Elicio Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Elicio Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elicio Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ELTX) was last updated on 5/30/2025 by MarketBeat.com Staff
Buy ELTX Stock Free ELTX Stock Alerts